Sublime
An inspiration engine for ideas
Harvard scientists are leaving academia for the private sector to fast-track biomedical breakthroughs. Michael Mina (eMed), Douglas Melton (Vertex), Stuart Schreiber (Arena Bioworks) cite funding delays & admin hurdles as key reasons. #BiomedicalResearch https://t.co/GBR42EfZkH
Jeffrey Millmanx.comI wrote about CRISPR & the dawn of engineered biology this week on foundations & frontiers 🧬 https://t.co/fbCmVIgXXD
anna-sofiax.comCHM Research
Mary Martin • 1 card
BREAKING NEWS
The Royal Swedish Academy of Sciences has decided to award the 2024 #NobelPrize in Chemistry with one half to David Baker “for computational protein design” and the other half jointly to Demis Hassabis and John M. Jumper “for protein structure prediction.” https://t.co/gYrdFFcD4T
This is true. We are probably going to 1,000x at least in next 5 - 7 years
and oh to think the investors who passed 😭😭😭 https://t.co/BRS5yOyXHW
At present only a fraction of synthesized DNA is screened for potentially dangerous elements, but a global effort like the SecureDNA program to plug every synthesizer—benchtop at home or large and remote—into a centralized, secure, and encrypted system that can scan for pathogenic sequences is a great start. If people are printing potentially
... See moreMustafa Suleyman • The Coming Wave: Technology, Power, and the Twenty-first Century's Greatest Dilemma
Biotech
Michael Tier • 1 card
Already a physician, Bradner went back for further study in chemistry with the goal of developing targeted drugs that can disable cancer cells’ growth at the molecular level. From the beginning,
Joel Gurin • Open Data Now: The Secret to Hot Startups, Smart Investing, Savvy Marketing, and Fast Innovation (Business Books)
Jefferson Curl